Condition
Follicular Helper T-Cell Lymphoma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Not Yet Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06724237Phase 3Recruiting
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
NCT07293403Phase 2Not Yet RecruitingPrimary
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
NCT07278856Phase 1Not Yet RecruitingPrimary
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
Showing all 3 trials